PLUVICTO 镥[177LU]特昔维匹肽

PLUVICTO (lutetium [177Lu] texivirpitide) is a targeted radioligand therapy (RLT) developed by Novartis Pharmaceuticals for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). ‌
Indications
It is indicated for adult patients who have received androgen receptor pathway inhibitors and are eligible for paclitaxel chemotherapy, or for mCRPC patients who have received paclitaxel chemotherapy. ‌
Drug mechanism
After intravenous injection into the body, it specifically binds to cancer cells expressing PSMA, and then releases beta rays to damage cancer cell DNA, preventing their proliferation or triggering cell death. This precision targeted therapy can reduce damage to surrounding healthy tissues. ‌
Efficacy and safety
In the pivotal Phase 3 clinical trial VISION study, PLUVICTO reduced the risk of death by 38%. Common adverse reactions include fatigue and nausea, and the dose needs to be adjusted according to individual conditions. ‌
Regulatory progress
It was approved for marketing by the US FDA in March 2022, with sales of US$1.39 billion in 2023. In September 2024, China’s National Medical Products Administration accepted its marketing application for the treatment of mCRPC in Chinese patients. ‌